Article
Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer
31 Jul 2020
Abstract excerpt
Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
